Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov:195:105180.
doi: 10.1016/j.antiviral.2021.105180. Epub 2021 Sep 20.

An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral

Justin G Julander  1 , James F Demarest  2 , Ray Taylor  2 , Brian B Gowen  3 , Dennis M Walling  2 , Amanda Mathis  2 , Y S Babu  2
Affiliations
Review

An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral

Justin G Julander et al. Antiviral Res. 2021 Nov.

Abstract

Galidesivir (BCX4430) is an adenosine nucleoside analog that is broadly active in cell culture against several RNA viruses of various families. This activity has also been shown in animal models of viral disease associated with Ebola, Marburg, yellow fever, Zika, and Rift Valley fever viruses. In many cases, the compound is more efficacious in animal models than cell culture activity would predict. Based on favorable data from in vivo animal studies, galidesivir has recently undergone evaluation in several phase I clinical trials, including against severe acute respiratory syndrome coronavirus 2, and as a medical countermeasure for the treatment of Marburg virus disease.

Keywords: Antiviral; Marburg virus; Nucleoside analog; RNA viruses; Yellow fever.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Amanda Mathis, PhD, Y. S. Babu, PhD, Ray Taylor, MBA, and Dennis M. Walling, MD, MMCI, FIDSA are employed by and own stock in BioCryst. James F. Demarest, PhD, is a contract consultant for BioCryst. Justin G. Julander, PhD, and Brian B. Gowen, PhD, have no disclosures.

Figures

Fig. 1
Fig. 1
Structure of galidesivir, an adenosine nucleoside analog (upper panel), and its active triphosphate form (lower panel).
See this image and copyright information in PMC

References

    1. Aftab S.O., Ghouri M.Z., Masood M.U., Haider Z., Khan Z., Ahmad A., Munawar N. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. J. Transl. Med. 2020;18:275. - PMC - PubMed
    1. Avsic-Zupanc T., Saksida A., Korva M. Hantavirus infections. Clin. Microbiol. Infect. 2019;21S:e6–e16. - PubMed
    1. BioCryst BioCryst initiates phase 1 clinical trial of galidesivir. 2019. https://ir.biocryst.com/news-releases/news-release-details/biocryst-init... press release, January 2, 2019.
    1. BioCryst . 2020. BioCryst Provides Update on Galidesivir Program.https://ir.biocryst.com/news-releases/news-release-details/biocryst-prov... press release, December 22, 2020.
    1. Bullard-Feibelman K.M., Govero J., Zhu Z., Salazar V., Veselinovic M., Diamond M.S., Geiss B.J. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antivir. Res. 2017;137:134–140. - PMC - PubMed

MeSH terms